News & Updates

Consolidation treatment with the PD-L1 antibody durvalumab following concurrent chemoradiotherapy significantly prolonged overall (OS) and progression-free survival (PFS) in patients with limited-stage small-cell lung cancer (SCLC), as shown in the interim analysis of the phase III ADRIATIC trial.

Patients with resectable nonsmall cell lung cancer (NSCLC) enjoy sustained survival from neoadjuvant nivolumab when added to chemotherapy compared with chemotherapy alone, as seen in the 4-year analysis from the phase III CheckMate 816 study.

A handheld, 6-lead electrocardiographic (ECG) device may be an effective triage test that could reduce the need for 12-lead ECG monitoring in resource-limited, rifampin-resistant tuberculosis (RR-TB) treatment settings, according to a diagnostic prospective cohort study.

A long-term study showed that individuals who have recovered from COVID-19 continued to experience cognitive, psychiatric, and neurological issues, as well as brain functional alteration, even 2 years after being infected.

Patients with postacute COVID-19 syndrome (PACS) may benefit from faecal microbiota transplantation (FMT) treatment, which helps reduce anxiety and improve sleep quality, suggests a study.

A combination regimen comprising the novel agent GST-HG171 (also known as atilotrelvir) and ritonavir improves clinical symptom recovery and viral clearance in low-risk vaccinated adults with mild-to-moderate COVID-19, findings from a pivotal phase II/III study have shown.

Overuse of short-acting β2 agonists (SABA) is prevalent among patients with asthma in Hong Kong and associated with an increased risk of all-cause mortality and hospital admissions, according to a local retrospective cohort study, which was part of the global SABINA (SABA Use in Asthma) research programme.

In the pivotal phase II/III ATOMIC-Meso* trial, adding the first-in-class, arginine-depleting agent pegargiminase to standard first-line platinum-pemetrexed chemotherapy prolongs overall survival (OS) and progression-free survival (PFS) in patients with treatment-naïve, nonresectable, nonepithelioid pleural mesothelioma.